Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial

Journal of the National Cancer Institute

Volumn 93, Issue 1, 2001, Pages 16-21

  Reis, Steven E ^a   Costantino, Joseph P ^b   Wickerham, D Lawrence ^c   Tan Chiu, Elizabeth ^c   Wang, Jiping ^b   Kavanah, Maureen ^d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FATALITY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035798788     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.1.16     Document Type: Article

References (22)

1. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
2. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer
3. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen
4. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary, arteries in nonhuman primates
5. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys
6. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
7. Highlights of the NSABP breast cancer prevention trial
8. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
9. Applications of crude incidence curves
10. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study
11. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' health study
12. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
13. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
14. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone
15. Estradiol accelerates functional endothelial recovery after arterial injury
16. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
17. The protective effects of estrogen on the cardiovascular system
18. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
19. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish breast cancer committee
20. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
21. A prospective study of postmenopausal estrogen therapy and coronary heart disease